Rating Icon
A
NCD

DISHMAN CARBOGEN AMCIS LIMITED

ISIN: INE385W07059

10.70%YTM
Payouts : Quarterly
Maturity Date : 20 Jan 2029
10.70%
YTM
₹ 1,00,986.56
Min Investment
Quarterly
Payout
₹ 1,00,000
Face Value
10.00%
Coupon
20 Jan 2029
Maturity Date
Currently subscribedLot Size : 50 Units available
0% Completed

Interest Calculator

InterestQuarterly

Sign up to view detailed payout schedule

About The Issuer

Dishman Carbogen Amcis Limited (DCAL) is a globally integrated CRAMS (Contract Research & Manufacturing Services) and specialty chemicals company serving innovator and generic pharmaceutical clients. The group offers end-to-end services across process R&D, scale-up, late-stage clinical and commercial manufacturing, including APIs, intermediates, high-potency APIs and Vitamin-D analogues. DCAL operates manufacturing and R&D facilities across India, Europe and other global locations through the Carbogen Amcis network and supplies to regulated markets.

Metric
FY23
Revenue (₹ cr)
2,412.9
Net Worth (₹ cr)
~5,810
EBITDA (₹ cr)
414.2 (Adj.)
PAT (₹ cr)
Moderated
Rating
IND A+/Stable
💡Issuer Health Summary

Key financial indicators to assess stability & repayment capacity.

Key Risks & Disclosures

Regulatory & Compliance Risk:DCAL’s European facilities have faced regulatory observations from EDQM in recent years, impacting production and profitability. Any adverse regulatory outcomes can affect exports, revenues and cash flows.
Client & Product Concentration:A meaningful share of revenues is driven by marketable molecules (vitamin D analogues, specialty chemicals). Demand cyclicality in pharma and pricing pressure in generics can impact earnings.
Global Operating Cost Volatility:High energy costs in Europe, currency volatility and compliance capex can materially affect margins and near-term profitability.
Project Execution & R&D Risk:CRAMS pipeline execution depends on successful scale-up and regulatory approvals of client molecules. Delays in client programs can lead to volatility in capacity utilisation.

Invest

Units

Trade & Settlement

Trade date
12 Mar 2026
Orders placed after 4 PM will be executed on the next business day.Weekends & exchange holidays are skipped.

Totals (For Selected Units)

Price per Unit
₹1,00,986.56
Investment amount
₹1,00,986.56
Total Interest
₹16,222.61
Total Receivable
₹1,16,222.61

Diligence Documents

Consent letter from DT 10.12.2025_20260120211756Download
NCD Rating Letter_20260120211756Download
Disclosure DocumentsDownload
KEY INFORMATION DOCUMENTDownload
Annexure V Shareholding Structure for quarter ended 30 09 2025Download
Annexure II Related Party TransactionsDownload
Annexure III ResolutionsDownload
Annexure VII Peer Review CertificateDownload
GENERAL INFORMATION DOCUMENTDownload
Equirize

EquiRize Securities Private Limited.

Legal & Compliance

Investor Charter Regulatory Disclosures Policies & Procedures Grievance Redressal Mechanism

Quick Links

Privacy Policy Terms & Conditions

Help

Contact Us

SEBI Registered

RBI Regulated FDs

Member with BSE & NSE

whatsapp-icon

Registered Office: 301 Chawla Complex Commercial Premises, Sector 15, CBD Belapur, Navi Mumbai 400614 Maharashtra

© 2025 EquiRize. All rights reserved. | CIN: U66190MH2024PTC430982 | SEBI Registration Number (Stock Broker): INZ000323730 | BSE Membership No. 6914 - Debt Segment | NSE Membership No. 90472 - Debt Segment

Compliance Officer:

Srilakshmi Deshmukh

compliance@EquiRize.com, +91-7993739228

Investments in debt securities, municipal debt securities, and securitised debt instruments carry risks, including potential delays or defaults in repayment. Please read all offer-related documents carefully before investing.

Complaint Redressal via SEBI SCORES:

(i) Register on the SCORES portal at scores.sebi.gov.in

(ii) Mandatory details: Name, PAN, Address, Mobile Number, Email ID

(iii) Benefits: Transparent communication and faster resolution of grievances

Investor Protection Guidelines:

  1. Prevent Unauthorised Transactions:
    • Update your mobile number and email ID with your Stock Broker and Depository Participant.
    • Receive transaction alerts directly from the Exchange and NSDL/CDSL the same day.
  2. IPO Application Process:
    • No need to issue a cheque. Mention your bank account number and sign the IPO application form to authorise payment via ASBA.
    • In case of non-allotment, funds remain in your bank account.
  3. KYC Compliance:
    • KYC is a one-time process. Once completed with a SEBI-registered intermediary (broker, DP, mutual fund, etc.), it is valid across all intermediaries.
  4. Stay Vigilant:
    • Beware of fraudsters sending bulk messages with fake investment tips or promises of guaranteed returns.
    • Do not engage in unauthorised portfolio management or collective investment schemes promising fixed/guaranteed returns.

Important Note: Fixed Deposits (FDs) and Peer to Peer (P2P) Lending are not exchange-traded products. EquiRize Securities solely connects investors/lenders with said products.

Attention Investors:

  • Stock Brokers can accept securities as margin only through pledge in the depository system (w.e.f. September 1, 2020).
  • Ensure your contact details are updated to receive OTPs directly from NSDL/CDSL for pledge creation.
  • Review your holdings regularly via the Consolidated Account Statement issued monthly by NSDL/CDSL.

Useful Links:

SEBI: https://www.sebi.gov.in

NSDL: https://www.nsdl.co.in

CDSL: https://www.cdslindia.com

NSE: https://www.nseindia.com

BSE: https://www.bseindia.com

SCORES 2.0: https://scores.sebi.gov.in

SMART ODR Portal: https://smartodr.in/login

Issued in the interest of investors by EquiRize Securities Private Limited.